385 related articles for article (PubMed ID: 36458011)
1. The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells.
Sánchez-León ML; Jiménez-Cortegana C; Cabrera G; Vermeulen EM; de la Cruz-Merino L; Sánchez-Margalet V
Front Immunol; 2022; 13():1050484. PubMed ID: 36458011
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
4. Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic Immunity.
Barnwal A; Gaur V; Sengupta A; Tyagi W; Das S; Bhattacharyya J
ACS Biomater Sci Eng; 2023 Nov; 9(11):6409-6424. PubMed ID: 37870457
[TBL] [Abstract][Full Text] [Related]
5. The immunomodulatory role of exosomal microRNA networks in the crosstalk between tumor-associated myeloid-derived suppressor cells and tumor cells.
Shokati E; Safari E
Int Immunopharmacol; 2023 Jul; 120():110267. PubMed ID: 37276829
[TBL] [Abstract][Full Text] [Related]
6. Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell-killing capability.
Ribechini E; Eckert I; Beilhack A; Du Plessis N; Walzl G; Schleicher U; Ritter U; Lutz MB
JCI Insight; 2019 Jun; 5(13):. PubMed ID: 31162143
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
Mortezaee K
Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
[TBL] [Abstract][Full Text] [Related]
9. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
10. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
11. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
13. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment.
Tian X; Shen H; Li Z; Wang T; Wang S
J Hematol Oncol; 2019 Aug; 12(1):84. PubMed ID: 31438991
[TBL] [Abstract][Full Text] [Related]
14. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
15. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
Kalathil SG; Thanavala Y
Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
[TBL] [Abstract][Full Text] [Related]
16. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
17. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
19. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status.
Nandre R; Verma V; Gaur P; Patil V; Yang X; Ramlaoui Z; Shobaki N; Andersen MH; Pedersen AW; Zocca MB; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2022 May; 10(5):571-580. PubMed ID: 35290437
[TBL] [Abstract][Full Text] [Related]
20. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.
van Gulijk M; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2759. PubMed ID: 30568653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
